The 2017 AHA/ACC/HRSGuideline for Management of Patients With Ventricular Arrhythmias (VA) and the Prevention of Sudden Cardiac Death (SCD) seeks to provides contemporary recommendations for the management of adults who have VA or who are at risk for SCD, including diseases and syndromes associated with a risk of SCD from VA. This guideline includes indications for implantable-cardioverter defibrillators for the treatment of VA and prevention of SCD, but it does not delve into details on individual device selection and programming, including considerations relevant to cardiac resynchronization therapy (CRT), bradycardia pacing, and hemodynamic monitoring, which have been covered elsewhere. This document is aimed at the adult population (≥18 years of age), offering no specific recommendations for pediatric patients, even though some pediatric data were examined.
Central Illustration: Indications for Implantable Cardioverter-Defibrillator (ICD) in Patients with Ischemic Heart Disease (IHD) to Prevent Sudden Cardiac Death (SCD)
Mechanisms of VA
General Evaluation of Patients with Documented or Suspected VA
Therapies for Treatment or Prevention of VA
Acute Management of Specific VA
Ongoing Management of VA and SCD Risk Related to Specific Disease States